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Abstract
Background:  Surgery, commonly performed after an overnight fast, causes a postoperative
decline in the anabolic and glucose lowering insulin-like growth factor-1 (IGF-1). Clinical fasting
studies have exhibited a positive correlation between IGF-1 and nitrogen balance during different
conditions. A perioperative amino acid infusion changes nitrogen balance and might thereby
influence serum IGF-1. We hypothesized that amino acid infusion would enhance IGF-1 and
thereby might influence glucose homeostasis after surgery. In this study we examined two different
regimes of perioperative amino acids infusion.
Methods: 24 females scheduled for abdominal hysterectomy were randomized into three groups;
Ringer's solution infusion throughout anesthesia (Group B), amino acid infusion throughout
anesthesia (Group C) and amino acid infusion 1 hour before anesthesia and during 1.5 hrs of
surgery (Group D). Six female volunteers, who were not operated, but received the same amino
acids infusion after fasting, served as controls (Group A). Fasting levels of IGF-1, Insulin-like growth
factor binding protein-1 (IGFBP-1), insulin and P-glucose were studied prior to, and four days
following, operation. Homeostasis model assessment (HOMA) was used as an index of insulin
resistance. Non-parametric statistical methods were used.
Results: During the study the Ringer-group exhibited a decrease in IGF-1 and an increase in insulin
and plasma glucose after surgery. Within the other groups there were no significant alterations
over time after surgery, with the exception of a postoperative decrease in IGF-1 in group D. Group
C had higher IGF-1 levels compared to group B on all days. Also, group D had higher IGF-1 levels
than group B on day 2 – 4. From baseline to the first postoperative day there was a significant
increase in HOMA and IGFBP-1 in groups B and C. These changes were not found in group D, in
which insulin, glucose, HOMA and IGFBP-1 did not change. Amino acid infusion to the volunteers
did not affect any of the variables studied.
Conclusion: Amino acid infusion during surgery attenuates the decrease in IGF-1 and diminishes
the "diabetes of injury".
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Background
Elective surgery is traditionally performed after an over-
night fast in order to reduce the risk of aspiration. It has
recently been shown that preoperative carbohydrate treat-
ment reduces insulin resistance after surgery with a shorter
length of hospital stay [1]. Shorter hospitalization has
also been reported after amino acid treatment during sur-
gery [2]. The insulin-like growth factor-1 (IGF-1) is a com-
mon denominator for amino acid and carbohydrate
metabolism [3]. The anabolic axis of growth hormone
(GH) and IGF-1 is sensitive to nutritional variations [4,5].
Fasting and catabolic states cause an uncoupling between
IGF-1 and GH with high serum levels of GH and low IGF-
1 [6]. Both sufficient energy and protein intake are neces-
sary for a normal IGF-1 response to GH. IGF-1 stimulates
amino acid and glucose uptake as well as protein synthesis
in muscle [3,7]. In humans, IGF-1 also reduces B-glucose
in parallel with insulin [8-10]. Circulating IGF-1 is pro-
duced in the liver and more than 99 % is bound to bind-
ing proteins (IGFBPs, 1–6) [4,11]. About 80–90% is
bound to a stable ternary protein complex consisting of
IGF-1, IGFBP-3 and Acid Labile Subunit (ALS) with a long
half-life (≈15 h)[12,13]. The ternary complex stabilize the
concentration of IGF-1 in plasma and regulates the efflux
of free IGF-1 from the vascular space [14]. The smaller
IGFBPs (IGFBP-1, -2, -4, -6) form binary complexes with
IGF-1 and do not bind to ALS. Only the free fraction,
which is less than 1% of total IGF-1, is supposed to be
active at the receptor[11]. After surgery [15,16] and during
pregnancy [17] and critical illness [18,19] an proteolytic
activity is observed which reduces the half-life of IGF-1. In
addition, serum levels of the smaller binding proteins are
often elevated during critical illness [20].
Insulin-like growth factor binding protein-1 (IGFBP-1),
produced in the liver [11,21], is an important regulator of
free IGF-1. Its production is inhibited by insulin at the
transcription level [22] and is stimulated by glucagon
[23], epinephrine [24] and cytokines [25]. IGFBP-1, free
IGF-1 and insulin all of them have a half-life about 5–10
minutes [11,13,26].
IGF-1 is also produced in other tissues, such as muscle,
and acts as a paracrine and autocrine growth factor [27].
This local production is also dependent on GH, and nutri-
tion [4,28].
A number studies in fasting subjects have described a close
correlation between total IGF-1 and nitrogen balance
[4,28]. Earlier studies have reported increased renal utili-
zation of amino acids with increasing blood concentra-
tion [29]. Thus infusion of amino acids ought to be
utilized by patients during surgery. In humans amino
acids act both as substrates and transmitters. The effect of
an amino acid infusion during surgery might thus be dif-
ferent if it is given before or after induction of anesthesia.
The postoperative effect of amino acid infusion given dur-
ing anesthesia and surgery concerning IGF-1 and glucose
homeostasis has previously not been elucidated. The aim
of this pilot study was to investigate the effect of two
regimes of amino acids infusion, before and during hys-
terectomy, on the surgery induced decrease in IGF-1 and
"diabetes of injury" [30].
Methods
Thirty women were included in the study. Patients with
known metabolic, hepatic or renal disorders were not
included in this study and none of the studied subjects
had reported any weight changes prior the investigation.
Neither of them was on any drug treatment. They were all
informed of the study and its risks before they consented
to participate. The study protocol was approved by the
Ethics Committee at Karolinska Hospital.
Study groups
The subjects were divided into four study groups. Six
female volunteers acted as a control group from the nor-
mal population (group A). They were fasting over night
but otherwise had no food restrictions during the study
and were given an i.v. amino acid infusion for 2.5 h, in an
amount that was similar to the two amino acid treated
patient groups. The volunteers were not hospitalized or
subjected to anesthesia or surgery. Twenty-four female
patients scheduled for hysterectomy due to myoma were
randomly divided into three groups (groups B, C, D).
Eight control patients were anaesthetized and received no
amino acids, but a corresponding volume (126 mL/h) of
Ringer's solution, (group B). Another group of 8 patients
received amino acid infusions starting at induction of
anesthesia and continuing throughout surgery until awak-
ening (group C). In group D, eight patients were given
amino acids during 1 h before induction of anesthesia and
for additional 1.5 h into anesthesia and surgery.
Anesthesia
Prior to anesthesia and surgery all patients were on an
unrestricted mixed diet. The estimated intake of nitrogen
and energy 24 h before the study were of the same magni-
tude in all groups. They were all fasted over-night and got
an oral premedication of lorazepam 1 mg 1 h prior to
anesthesia. Before induction of anesthesia two cubital
veins were catheterized. One catheter for amino acid infu-
sion or acetated Ringer's solution was inserted and
advanced centrally 30 cm to reach a tip position in the
subclavian vein. The venous catheter in the other arm was
used for anesthetic drug administration. Anesthesia was
induced with thiopental, 5 mg/kg, and the trachea was
intubated after a bolus dose of atracurium 0.5 mg/kg fol-
lowed by a continuous infusion of 0.5 mg/kg/h. Anesthe-
sia was maintained with 1–2% of isoflurane in O2/N2O.Nutrition & Metabolism 2007, 4:2 http://www.nutritionandmetabolism.com/content/4/1/2
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Fresh gas flows were set at 2 L/min of O2 and 4 L/min of
N2O, using a partial rebreathing circuit (Dameca ventila-
tor 109 40, Dameca, Rødøvre, Denmark). Usual monitors
were used. Before the start of surgery fentanyl 3 µg/kg was
given. The atracurium infusion was stopped 0.5 h before
the end of the operation, and muscle relaxation was
antagonized with 2.5 mg of neostigmine and 0.5 mg of
glycopyrrolate at the end of surgery. Postoperatively, pain
relief was standardized and given according to routine as
needed.
During anesthesia and surgery, 500 mL/h of Ringer's solu-
tion was infused i.v. in all patients. After emergence from
anesthesia, 1000–1500 mL of a 5 % glucose solution was
administered in all patients until the next morning. The
first postoperative day the patients were on a liquid diet.
From the second day after surgery the patients had regular
meals. All postoperative energy and nitrogen intake was
daily recorded throughout the study. Energy and nitrogen
intake were equal during each postoperative day in the
three patient groups.
Amino acid infusion
All studies commenced at 7.30 a.m Healthy volunteers
(group A) reported in the morning after an overnight fast.
They received a balanced amino acid mixture (Vamin® 18
g N/L, Pharmacia, Stockholm, Sweden) at a rate of 126
mL/h, corresponding to 240 kJ of energy per h. The mix-
ture of amino acids in Vamin® 18 g N/L is presented in
Table 1. Thus, during 2.5 h of infusion, the subjects in
group A received 600 kJ of extra energy from amino acids
and totally 397 mmoles nitrogen was infused. The
patients in group D, in which the amino acid infusion
started 1 h before induction of anesthesia and continued
during the first 1.5 h of anesthesia and surgery, received
exactly the same amounts of energy and nitrogen, i.e. 600
kJ and 397 mmoles, respectively. The patients in group C
received an identical amino acid infusion throughout
anesthesia and obtained 384 ± 24 mmoles (mean ± SEM)
of nitrogen. The patients' ward nurses, as well as surgeons,
were unaware of whether amino acids or saline was given.
Otherwise the study was not blinded.
Measurements and analyses
Blood samples were taken, after an overnight fast, in the
mornings of the day of surgery and during the first four
postoperative days. Blood samples were stored cold and
centrifuged within 2 h. Serum was frozen at -80°C. Sam-
ples were analyzed at the same occasion after the study
was completed. IGF-1, IGFBP-1, insulin and plasma-glu-
cose were analyzed. Serum concentrations of total IGF-I
were determined by RIA after acid ethanol extraction to
minimize interference with IGFBPs [31]. The truncated
des (1–3) IGF-I that has reduced affinity for IGFBPs was
used as the radioligand in the IGF-I RIA. IGFBP-1 was
determined in serum by RIA as described by Povoa et al.
[32].
Insulin was measured with a commercial RIA-kit, Pharma-
cia Insulin (Pharmacia, Stockholm, Sweden) and plasma
glucose was analyzed by an enzymatic electrochemical
method using a glucose analyzer (YSI, Yellow Springs,
OH).
HOMA (Homeostasis model assessment) a index of insu-
lin resistance: p-glucose × p-insulin/22.5 [33].
Statistics
Non-parametric statistical methods were used for the sta-
tistical analyses since the biochemical data was not nor-
mally distributed. Mann-Whitney test was initially used
for preoperative comparisons between groups. Friedmans
ANOVA was used to test postoperative alterations of the
variables in the groups. If the ANOVA showed significance
another Mann-Whitney test was performed for each post-
operative day for comparisons between groups after sur-
gery.
Finally, Wilcoxon signed rank test was done for a compar-
ison of preoperative baseline levels with the values the day
after surgery. All statistical analyses were performed with
SPSS (Chicago, Il). A p value ≤ 0.05 was considered as an
indication of statistical significance.
Results
There were no significant differences between the four
groups with regard to age, weight, and height (Table 2).
Duration of anesthesia and surgery were also similar in
the three operated patient groups (Table 2).
The value of blood analyses are displayed by groups for
each single patient and variable in Figure 1, 2, 3, 4, 5.
Table 1: The content of amino acids in – Vamin® 18 – per 1000 mL.
glycine 7.9 g histidine 6.8 g proline 6.8 g
aspartate 3.4 g isoleucine 5.6 g serine 4.5 g
glutamate 5.6 g leucine 7.9 g threonine 5.6 g
alanine 16.0 g lysine 9.0 g tryptophan 1.9 g
arginine 11.3 g methionine 5.6 g tyrosine 230 mg
cysteine 560 mg phenylalanine 7.9 g valine 7.3 g.Nutrition & Metabolism 2007, 4:2 http://www.nutritionandmetabolism.com/content/4/1/2
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Results are also presented in Figure 6, 7, 8, 9, 10 as
median, first and third quartile for each analyte and is also
described in the text below. Among the operated patients,
group C had a significantly lower level of IGFBP-1 before
surgery than group B and D (Figure 5 &10). Regarding the
other variables, there were no significant differences
between the groups at baseline.
During the study period Group B, the Ringer-group,
exhibited a decrease in IGF-1 (from 139 to 91 µg/L; p =
0.002, Figure 1 &6) and an increase in insulin (from 6
to18 mU/L; p < 0.02, Figure 2 &7) as well plasma glucose
(from 3.9 to 4.7 mmol/L; p < 0.05, Figure 3 &8) after sur-
gery. HOMA was increased (from 0.8 to 3.7) but did not
reach significance (p = 0.07, Figure 4 &9). IGFBP-1 was
unchanged (Figure 5 &10). Within the other groups there
were no significant alterations over time after surgery in
any variable, with the exception of IGF-1 in group D
which decreased postoperatively from 153 to116 µg/L (p
< 0.05, Figure 1 &6). Group C had significantly higher
IGF-1 levels compared to group B on all postoperative
days (p < 0.05, Figure 6). Also group D had significantly
higher IGF-1 levels than group B, but only on day 2 – 4
after surgery (p < 0.05, Figure 6). No significant differ-
ences in IGF-1 levels occurred between groups C and D.
From baseline to the first postoperative day there was a
significant increase in group B and C in HOMA (from 0.8
to1.3 and 1.2 to1.8 respectively; p < 0.05, Figure 9) and
IGFBP-1 (from 35 to45 µg/L and 16 to23 µg/L; p < 0.05,
Figure 10). The increase in insulin in group B (6 to 7 mU/
L; p = 0.06) and C (6 to 9 mU/L; p = 0.02) only reached
significance for group C (Figure 7). Group B was the only
group that had a postoperative increase in P-glucose (3.9
to 4.3 mmol/L; p < 0.05, Figure 8). These changes were
not found in group D, in which insulin, glucose, HOMA
and IGFBP-1 did not change significantly. IGF-1, however,
decreased in both group B (139 to101 µg/L; p < 0.05) and
group D (153 to132 µg/L; p < 0.05) the first postoperative
day (Figure 6).
Amino acid infusion given to fasted volunteers did not
affect any of the variables studied, neither on the first
postoperative day nor during the study period.
Discussion
Our study shows that an amino acid infusion during sur-
gery attenuates the surgery-induced decline in IGF-1. This
effect was most pronounced in the group who received
amino acids throughout anesthesia. A decrease in IGF-1
during surgery is a general phenomenon described after
both abdominal, heart and hip surgery [19,34-36] during
different types of anesthesia. In the present study surgery
was performed during the same type of anesthesia so the
influence of anesthetic agents would not obscure the
interpretation of the intervention.
The preserved IGF-1 levels found in the present study will
most probably be a clinically important finding since
reduced levels of IGF-1 are linked with postoperative
catabolism. Protracted postoperative catabolism is a risk
factor for complications and prolonged hospitalization.
Administration of high doses of GH perioperatively has
shown that retained IGF-1 levels are associated with
improved nitrogen balance [37,38]. However, GH-treat-
ment perioperatively is unsuitable since GH-treated criti-
cally ill patients, in two large randomized studies, had
doubled mortality compared to their controls [39]. The
mechanism behind this unexpected dramatic adverse
effect by rhGH-treatment is still unknown but supposed
to be caused by GHs immune modulating effect or GHs
secondary negative effect on glucose homeostasis [40].
IGF-1 is not suspected and in a review IGF-1 was demon-
strated to be safe [41]. Actually, maintained or restored
IGF-1 levels have a potential to confer long term health
benefits. Retained concentration of IGF-1 reduces the risk
of diabetes, sarcopenia and cognitive attenuation [42,41]
and in elderly also the risk of ischemic heart diseases [43].
Thus, to maintain IGF-1 after surgery in a cost-effective
and safe manner may be beneficial.
Preserved levels of IGF-1 after surgery has previously oth-
erwise only been reported when extremely high doses of
insulin were given together with glucose and potassium
(GIK) during heart surgery [35]. The present study shows
that it actually also is possible to influence the postopera-
tive decrease in IGF-1 with a balanced amino acid mixture
supply.
Table 2: Demographic data, duration of anesthesia and surgery for 24 patients and 6 volunteers without surgery.
Study Groups n Age (year) Weight (kg) Height (cm) Duration of anesthesia (min) Duration of surgery (min)
Group A 6 50 ± 3 63 ± 3 170 ± 2 - -
Group B 8 50 ± 2 64 ± 2 165 ± 1 125 ± 8 92 ± 6
Group C 8 48 ± 1 68 ± 3 163 ± 2 121 ± 9 94 ± 9
Group D 8 48 ± 2 61 ± 1 164 ± 2 120 ± 5 87 ± 4
Demographic data, duration of anesthesia and surgery for 24 patients scheduled for hysterectomy and 6 volunteers without surgery. Group A = 
Amino acid infusion but no anesthesia or surgery; Group B = Ringer's solution infusion throughout anesthesia; Group C = Amino acid infusion 
throughout anesthesia; Group D = Amino acid infusion started 1 h before anesthesia and during 1.5 h of surgery. Values are mean ± SEM.Nutrition & Metabolism 2007, 4:2 http://www.nutritionandmetabolism.com/content/4/1/2
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Fasting IGF-1 for each patient sorted by groups Figure 1
Fasting IGF-1 for each patient sorted by groups.
Fasting insulin for each patient by sorted groups Figure 2
Fasting insulin for each patient by sorted groups. 
Patient D5:s sample day 3 is probably not a true fasting 
value since it is only at this day she has increased levels of 
insulin and glucose.Nutrition & Metabolism 2007, 4:2 http://www.nutritionandmetabolism.com/content/4/1/2
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Fasting P-glucose for each patient sorted by groups Figure 3
Fasting P-glucose for each patient sorted by groups. 
Patient D5:s sample day 3 is probably not a true fasting 
value since it is only at this day she has increased levels of 
insulin and glucose.
HOMA for each patient sorted by groups Figure 4
HOMA for each patient sorted by groups. Patient 
D5:s sample day 3 is probably not a true fasting value since 
it is only at this day she has increased levels of insulin and 
glucose.Nutrition & Metabolism 2007, 4:2 http://www.nutritionandmetabolism.com/content/4/1/2
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Fasting IGFBP-1 for each patient sorted by groups Figure 5
Fasting IGFBP-1 for each patient sorted by groups.
Median, first and third quartile for IGF-1 by groups Figure 6
Median, first and third quartile for IGF-1 by groups. 
Patient D5s sample day 3 is withdrawn in these figure since it 
is considered to be a false fasting sample (figure 2 - 4). Signifi-
cant alteration (p < 0.05) tested by Friedman ANOVA during 
the study is marked *. Postoperative significant (p < 0.05) dif-
ferences in IGF-1 between group B and the amino acid 
groups are marked C and D respectively. Significant (p < 
0.05) difference between baseline and the first postoperative 
day is marked #.
Median, first and third quartile for insulin by groups Figure 7
Median, first and third quartile for insulin by groups. 
Patient D5s sample day 3 is withdrawn in these figure since it 
is considered to be a false fasting sample (figure 2 - 4). Signifi-
cant alteration (p < 0.05) tested by Friedman ANOVA during 
the study is marked *. Significant (p < 0.05) difference 
between baseline and the first postoperative day is marked #.Nutrition & Metabolism 2007, 4:2 http://www.nutritionandmetabolism.com/content/4/1/2
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The protracted "diabetes of injury" usually seen after sur-
gery existed in the Ringer-group but was attenuated in the
amino acid groups. In particular, amino acid infusion
before and during surgery totally abolished the increase in
insulin, and diminished the increase in IGFBP-1 and
HOMA seen in the other operated groups on the first post-
operative day.
Improved glucose control during cardiac surgical proce-
dures decreases the risk for postoperative complications
[44]. Furthermore, tight blood glucose control, with
intensive insulin therapy, dramatically reduces mortality
and morbidity in critically ill patients [30]. These findings
indicate that our results, that amino acids infusion
improves glucose homeostasis, might be clinically impor-
tant.
There are some possible explanations why amino acid
infusion might attenuate the surgery induced protracted
insulin resistance. First, the preserved levels of IGF-1 in
the amino acid groups might contribute since increased
levels of IGF-1 is shown to reduce insulin resistance [8,9].
However, Skjaerbaek et al. found unchanged levels of free
IGF-1 despite a significant decrease of total IGF-1 after sur-
gery[45]. They suggest that the increased protelytic activity
preserves the level of free IGF-1. Free IGF-1 was not meas-
ured in the present study so the preserved levels of IGF-1
may not completely explain the improved glucose home-
ostasis in the amino acid groups. Hence, other mecha-
nisms had to be considered.
The balanced amino acid mixture used in the study con-
tains L-Arginine, a precursor for NO. L-arginine acutely
initiates the secretion of insulin, glucagon and GH. Both
intravenous infusion [46], and long-term oral administra-
tion in diabetic patients [47] of L-arginine have been dem-
onstrated to improve insulin sensitivity. The dose of L-
arginine, given in our study, is compatible with the low-
dose used by Wascher et al[46]. Hence, this effect of L-
arginine might be of importance.
The greatest effect of a perioperative amino acid infusion
on the short-acting IGFBP-1 and insulin was seen at the
first day after surgery. On the day after surgery, the group
receiving amino acid infusion before and during the first
part of surgery (D) had lower levels of insulin than the
Median, first and third quartile for HOMA by groups Figure 9
Median, first and third quartile for HOMA by groups. 
Patient D5s sample day 3 is withdrawn in these figure since it 
is considered to be a false fasting sample (figure 2 - 4). Signifi-
cant (p < 0.05) difference between baseline and the first 
postoperative day is marked #.
Median, first and third quartile for P-glucose by groups Figure 8
Median, first and third quartile for P-glucose by 
groups. Patient D5s sample day 3 is withdrawn in these fig-
ure since it is considered to be a false fasting sample (figure 2 
- 4). Significant alteration (p < 0.05) tested by Friedman 
ANOVA during the study is marked *. Significant (p < 0.05) 
difference between baseline and the first postoperative day is 
marked #.
Median, first and third quartile for IGFBP-1 by groups Figure 10
Median, first and third quartile for IGFBP-1 by 
groups. Patient D5s sample day 3 is withdrawn in these fig-
ure since it is considered to be a false fasting sample (figure 2 
- 4). Preoperative difference between group C and the other 
groups in IGFBP-1 is marked C. Significant (p < 0.05) differ-
ence between baseline and the first postoperative day is 
marked #.Nutrition & Metabolism 2007, 4:2 http://www.nutritionandmetabolism.com/content/4/1/2
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patients receiving amino acids only during surgery (C).
The most probable reason for this is the different regimes
of amino acid administration. An infusion of amino acids
in rats caused a decrease in IGFBP-1 without any changes
in insulin [48]. A decrease in IGFBP-1 with unchanged
insulin levels is known to reflect an improved hepatic
insulin sensitivity [49]. Furthermore, the free glucose low-
ering fraction of IGF-1 depends on changes in IGFBP-1,
the only binding protein demonstrated to have acute met-
abolic effects [50]. In the amino acid-treated rats, a higher
concentration of total IGF-1 was detected [48] in agree-
ment with our findings. Our results suggest that preoper-
ative amino acid infusion has a pharmacological effect
and preserves IGFBP-1 postoperatively in traumatized
individuals. Consequently, the timing of the amino acids
infusion might be of importance for the metabolic
response.
Our patient groups were unfortunately not perfectly
matched at baseline. The lower levels of IGFBP-1 and a
tendency to greater body weight in group C, may suggest
an alternative explanation of the difference in insulin pat-
tern between groups C and D. Individuals that have low
IGFBP-1 before surgery (patients C1, C3, C6) have also
high insulin levels postoperatively, figures 1, 2, 3, 4, 5.
From earlier studies it is known that obesity, low levels of
IGFBP-1 and an increased IGF-1:IGFBP-1 ratio are factors
associated with insulin resistance in men and women
[49,51]. This possibly altered basal metabolism in some
of the individuals in group C might be an additional rea-
son for the different metabolic pattern between the two
treatment groups.
In the Ringer-group we found a pathological metabolic
pattern after operation, with depressed IGF-1 and pro-
tracted increased levels of glucose and insulin. In both
treatment groups, amino acid infusion attenuated the sur-
gery related decline in IGF-1, and improved glucose
homeostasis. However, in none of the amino acid groups
the amino acid regime were optimized. The optimal dose
and timing of perioperative amino acid therapy need to be
clarified in larger studies. The amino acid infusion could
probably start well ahead of anaesthesia and continue
during surgery. At least 60 minutes prior to anaesthesia
seems to be appropriate. A possible advantage of a contin-
ued infusion after operation has also to be investigated.
The exact mechanism behind this favourable effect has
also to be elucidated in further studies.
Conclusion
Our study shows that amino acid infusion during surgery
reduces the decrease in IGF-1. It also indicates that amino
acid therapy before and during surgery diminishes "diabe-
tes of injury". Larger studies are required to find out doses,
timing and mechanisms behind the favourable effects of
amino acid therapy during surgery.
Our findings might change the perioperative infusion
therapy in the future.
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